PAI
IOVA icon

Palo Alto Investors’s Iovance Biotherapeutics IOVA Stock Holding History

Palo Alto Investors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22M Sell
5,296,209
-1,053,354
-17% -$4M 3.04% 11
2026
Q1 		$22.3M Sell
6,349,563
-767,113
-11% -$2.45M 3.41% 11
2025
Q4 		$19.4M Sell
7,116,676
-501,456
-7% -$1.16M 2.7% 11
2025
Q3 		$16.5M Buy
7,618,132
+4,188,803
+122% +$9.89M 3.06% 9
2025
Q2 		$5.9M Buy
3,429,329
+218,015
+7% +$542K 1.26% 19
2025
Q1 		$10.7M Buy
3,211,314
+169,629
+6% +$875K 2.04% 14
2024
Q4 		$22.5M Hold
3,041,685
– – 3.49% 11
2024
Q3 		$28.6M Buy
3,041,685
+925,282
+44% +$8.77M 3.71% 10
2024
Q2 		$17M Buy
2,116,403
+3,592
+0.2% +$38.5K 1.97% 12
2024
Q1 		$31.3M Buy
2,112,811
+6,019
+0.3% +$70.1K 3.53% 9
2023
Q4 		$17.1M Buy
+2,106,792
New +$11M 1.54% 14

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Palo Alto Investors's IOVA Position: Q2 2026 in Review

Palo Alto Investors reduced its Iovance Biotherapeutics (IOVA) stake by 17% in Q2 2026, selling an estimated $4M and leaving 5,296,209 shares worth $22M. The position accounts for 3.04% of the portfolio, ranked #11.

Palo Alto Investors first reported a position in IOVA in Q4 2023 and has held it in 11 quarters since. The position peaked at $31.3M in Q1 2024. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Palo Alto Investors held 5,296,209 shares of Iovance Biotherapeutics worth $22M as of Q2 2026.
  • Palo Alto Investors sold 1,053,354 Iovance Biotherapeutics shares in Q2 2026, an estimated $4M.
  • Iovance Biotherapeutics made up 3.04% of Palo Alto Investors's portfolio in Q2 2026, its #11 holding.
  • Palo Alto Investors first reported a position in Iovance Biotherapeutics in Q4 2023 and has held it in 11 quarters since.
  • Palo Alto Investors's Iovance Biotherapeutics position peaked at $31.3M in Q1 2024.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Palo Alto Investors's 13F filing for Q2 2026, filed 17 Aug 2026.